Edition:
United States

Orion Oyj (ORNBV.HE)

ORNBV.HE on Helsinki Stock Exchange

36.78EUR
22 Jul 2016
Change (% chg)

€-0.11 (-0.30%)
Prev Close
€36.89
Open
€36.61
Day's High
€37.10
Day's Low
€36.51
Volume
276,355
Avg. Vol
223,425
52-wk High
€38.55
52-wk Low
€27.79

ORNBV.HE

Chart for ORNBV.HE

About

Orion Oyj is a Finland-based company engaged in the development, manufacture and marketing of pharmaceuticals and diagnostic tests. The Company operates, along with its subsidiaries, in two business segments: the Pharmaceuticals business segment develops, manufactures and markets pharmaceuticals and active pharmaceutical... (more)

Overall

Beta: 0.58
Market Cap(Mil.): €5,193.15
Shares Outstanding(Mil.): 141.26
Dividend: 1.30
Yield (%): 3.53

Financials

  ORNBV.HE Industry Sector
P/E (TTM): 24.24 35.74 36.72
EPS (TTM): 1.52 -- --
ROI: 28.99 15.07 14.32
ROE: 43.43 16.13 15.54

BRIEF-Orion Q2 EBIT beats expectations at EUR 83.5 million

* Q2 EBIT 83.5 million euros ($92.4 million) (Reuters poll 74.4 million euros)

Jul 19 2016

BRIEF-Orion Corporation and Asahi Kasei enters into global strategic collaboration

* Says that it has entered into a global strategi collaboration agreement with Japanese Asahi Kasei Pharma for the discovery, development and commercialisation of assets in pain management

Jun 22 2016

BRIEF-Orion completes share buyback

* Bought total of 500,000 own B shares at average price of about 33.5319 euros per share

Jun 16 2016

BRIEF-Orion upgrades full-year outlook for 2016

* Now sees 2016 operating profit without potential capital gains is estimated to exceed 270 million euros (operating profit was 267 million euros in 2015

Jun 15 2016

BRIEF-Orion and Bayer start new phase III study of prostate cancer drug

* Says Orion and Bayer expand clinical development program for ODM-201 and initiate a new phase III study Arasens in patients with metastatic hormone-sensitive prostate cancer

Jun 03 2016

BRIEF-Finland's Orion to buy back shares

* 500,000 class B shares will be acquired, acquisition will be started at earliest on 4 May and it can continue until further notice Further company coverage: (Helsinki Newsroom)

Apr 27 2016

Finland's Orion beats market expectations in first quarter

HELSINKI, April 27 Finnish drug maker Orion on Wednesday reported better than expected quarterly results as revenue from its asthma treatment products helped offset falling sales of its Parkinson's disease drug which faced increased generic competition.

Apr 27 2016

BRIEF-Orion to launch new incentive plan for key persons

* Says board of directors of Orion Corporation decided on an incentive plan for key persons

Feb 02 2016

Finland's Orion reports falling fourth-quarter profit, shares drop

HELSINKI, Feb 2 Finnish drug maker Orion on Tuesday reported a 8 percent drop in its fourth-quarter operating profit due to increased competition from generic drug makers.

Feb 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.